接受全身性癌症治疗的长者出现严重治疗相关毒性（TRT）的风险较高。现有的预测工具如 CARG 及 CRASH 在华人族群中的适用性有限，且未能全面涵盖与较新疗法（包括免疫治疗及靶向治疗）相关的毒性。
适应症：Cancer (Solid Tumors)、Geriatric Oncology
入组条件
纳入标准
- Aged 65 or above
- A diagnosis of lung cancer, gastrointestinal cancer, breast cancer, prostate cancer, and uterine cancer with histological confirmation or radiological diagnosis\*\*
- Seen by the oncologist and scheduled to receive a new systemic anti-cancer treatment, including chemotherapy, targeted therapy, and immunotherapy, in either radical or first/second-line palliative intent. The planned treatment regimen is expected to last for at least 3 months.
- ECOG performance status of 0-2
- Agreement for treatment according to the TRTRM (ACTTOP) -risk strategy if in the TRTRM (ACTTOP) -informed care group
- Fluent in English or Chinese
- Valid consent obtained \*\* Only these five types of cancer are included to reduce the heterogeneity of the patients, as they are the top 5 cancers in Hong Kong.
排除标准
- Planned for radiotherapy alone
- Planned for systemic treatment concomitant with radiotherapy
- Scheduled to have hormonal therapy alone e.g. tamoxifen, aromatase inhibitors, luteinizing hormone-releasing hormone agonist (LHRHa)
- Planned for surgery within 3 months
- Dementia or patient mentally not fit for consent
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。